Lena K. L. Oestreich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lena K. L. Oestreich has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Marta Isabel Garrido
Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Australia
8 shared publications Thomas J. Whitford
School of Psychology, University of New South Wales, Sydney, NSW, Australia
8 shared publications- Roshini Randeniya
Queensland Brain Institute, The University of Queensland, Australia
5 shared publications - Julie D. Henry
School of Psychology, The University of Queensland, Brisbane, Australia
4 shared publications Paul Wright
Department of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom
4 shared publications- Sarah P. Coundouris
School of Psychology, The University of Queensland, Brisbane, Australia
4 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Taylor & Francis in European Journal of Psychotraumatology
- Vol. 17 (1)
Complex post-traumatic stress disorder in refugees, asylum seekers, and internally displaced people: a systematic review and meta-analysis
Complex post-traumatic stress disorder (CPTSD) was formally recognised in the International Classification of Diseases (ICD-11) as a trauma-related disorder distinct from post-traumatic stress diso...
- 20 October 2026
- Published by Taylor & Francis in European Journal of Psychotraumatology
- Vol. 17 (1)
Open AccessComplex post-traumatic stress disorder in refugees, asylum seekers, and internally displaced people: a systematic review and meta-analysis
Complex post-traumatic stress disorder (CPTSD) was formally recognised in the International Classification of Diseases (ICD-11) as a trauma-related disorder distinct from post-traumatic stress diso...
- Open Access
Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study
Neuroplasticity, the brain's capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [11C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprotein 2A (SV2A) density, offers the most direct in vivo measure of human synaptic density, but its relationship to complementary, more scalable neuroimaging measures of structural and functional plasticity remains uncharacterised. We combined [11C]-UCBJ PET, diffusion weighted imaging (DWI/NODDI), resting-state functional magnetic resonance imaging (rs-fMRI), and electroencephalography (EEG)-based sensory tasks (roving mismatch negativity, MMN; visual long-term potentiation, vLTP) in 18 healthy volunteers to test the relationship between synaptic terminal SV2A density and complementary structural and functional neuroplasticity measures, and whether these relationships were reproducible following pharmacological challenge with ketamine (n = 11) or N,N-dimethyltryptamine (DMT; n = 7). There were no statistically significant differences in PET-derived SV2A binding potential (BPND), DWI-derived neurite orientation dispersion (ODI) and structural weighted degree (SWD), EEG-derived MMN repetition suppression, and late-phase vLTP P2 potentiation, 1 to 8 days following DMT and ketamine exposure compared to baseline. BPND was coupled with ODI across cortical regions before and after pharmacological challenge, and this relationship was tighter within visual, attentional, and frontoparietal control brain networks. SWD showed a weaker, more spatially restricted association with BPND, primarily in regions belonging to the limbic and visual brain networks, but was not replicated post-drug. No consistent association was found between BPND and functional weighted degree (FWD), derived from rs-fMRI, at baseline or after pharmacological challenge. Frontotemporal BPND was positively associated with MMN repetition suppression (r = 0.61), and occipital BPND with late-phase vLTP P2 potentiation (r = 0.54), with the MMN-BPND association replicating after pharmacological challenge (r = 0.49). These findings link synaptic terminal SV2A density in the living human brain to neurite architecture and the capacity for short-term and Hebbian-like long-term synaptic plasticity, while dissociating these relationships from generic functional connectivity and magnitude of sensory-evoked responses. These data provide cross-modal validation for DWI- and EEG-derived measures as biological indices and surrogate measures of human synaptic plasticity.
Open AccessNeurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study
Neuroplasticity, the brain's capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [11C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprotein 2A (SV2A) density, offers the most direct in vivo measure of human synaptic density, but its relationship to complementary, more scalable neuroimaging measures of structural and functional plasticity remains uncharacterised. We combined [11C]-UCBJ PET, diffusion weighted imaging (DWI/NODDI), resting-state functional magnetic resonance imaging (rs-fMRI), and electroencephalography (EEG)-based sensory tasks (roving mismatch negativity, MMN; visual long-term potentiation, vLTP) in 18 healthy volunteers to test the relationship between synaptic terminal SV2A density and complementary structural and functional neuroplasticity measures, and whether these relationships were reproducible following pharmacological challenge with ketamine (n = 11) or N,N-dimethyltryptamine (DMT; n = 7). There were no statistically significant differences in PET-derived SV2A binding potential (BPND), DWI-derived neurite orientation dispersion (ODI) and structural weighted degree (SWD), EEG-derived MMN repetition suppression, and late-phase vLTP P2 potentiation, 1 to 8 days following DMT and ketamine exposure compared to baseline. BPND was coupled with ODI across cortical regions before and after pharmacological challenge, and this relationship was tighter within visual, attentional, and frontoparietal control brain networks. SWD showed a weaker, more spatially restricted association with BPND, primarily in regions belonging to the limbic and visual brain networks, but was not replicated post-drug. No consistent association was found between BPND and functional weighted degree (FWD), derived from rs-fMRI, at baseline or after pharmacological challenge. Frontotemporal BPND was positively associated with MMN repetition suppression (r = 0.61), and occipital BPND with late-phase vLTP P2 potentiation (r = 0.54), with the MMN-BPND association replicating after pharmacological challenge (r = 0.49). These findings link synaptic terminal SV2A density in the living human brain to neurite architecture and the capacity for short-term and Hebbian-like long-term synaptic plasticity, while dissociating these relationships from generic functional connectivity and magnitude of sensory-evoked responses. These data provide cross-modal validation for DWI- and EEG-derived measures as biological indices and surrogate measures of human synaptic plasticity.
- Open Access
- 29 September 2026
- Published by Center for Open Science in PsyArXiv
Diffusion MRI Metrics as Markers of Neuroinflammation in Mental Illness
Neuroinflammatory mechanisms are increasingly implicated in mental illness, but their characterization in the living human brain remains challenging. Diffusion magnetic resonance imaging (dMRI) is sensitive to tissue microstructure and offers a scalable approach for studying immune-related brain changes, yet it does not measure inflammation directly. Inflammatory processes alter the cellular and extracellular geometry that constrains water diffusion, and glial activation, edema, demyelination, and axonal injury may produce overlapping or opposing diffusion signatures. This review evaluates the extent to which commonly used and emerging dMRI metrics can support an inflammatory interpretation. It distinguishes signal representations, including diffusion tensor and kurtosis imaging, from biophysical models such as free-water imaging, neurite orientation dispersion and density imaging, diffusion basis spectrum imaging, and newer compartment models, and examines their mechanistic sensitivity and limitations. A review of studies combining dMRI with immune-related measures in psychiatric populations identified a heterogeneous literature dominated by small samples, peripheral biomarkers, and within-group associations. Free-water measures showed the most consistent associations with inflammatory markers, whereas tensor-derived findings were variable and large population studies indicated very small effect sizes. Evidence from compartment models, molecular imaging, and intervention studies remains sparse. Validation studies in experimental, histological, ex vivo, and cellular systems demonstrate that diffusion signals can reflect immune-related microstructural change but are not specific to inflammation. Future work should prioritize multimodal validation, mechanistically informed acquisition and modeling, and explicit testing of competing explanations. Once validated, dMRI could provide a scalable means of mapping immune-related microstructural change across the brain in mental illness.
- 29 September 2026
- Published by Center for Open Science in PsyArXiv
Open AccessDiffusion MRI Metrics as Markers of Neuroinflammation in Mental Illness
Neuroinflammatory mechanisms are increasingly implicated in mental illness, but their characterization in the living human brain remains challenging. Diffusion magnetic resonance imaging (dMRI) is sensitive to tissue microstructure and offers a scalable approach for studying immune-related brain changes, yet it does not measure inflammation directly. Inflammatory processes alter the cellular and extracellular geometry that constrains water diffusion, and glial activation, edema, demyelination, and axonal injury may produce overlapping or opposing diffusion signatures. This review evaluates the extent to which commonly used and emerging dMRI metrics can support an inflammatory interpretation. It distinguishes signal representations, including diffusion tensor and kurtosis imaging, from biophysical models such as free-water imaging, neurite orientation dispersion and density imaging, diffusion basis spectrum imaging, and newer compartment models, and examines their mechanistic sensitivity and limitations. A review of studies combining dMRI with immune-related measures in psychiatric populations identified a heterogeneous literature dominated by small samples, peripheral biomarkers, and within-group associations. Free-water measures showed the most consistent associations with inflammatory markers, whereas tensor-derived findings were variable and large population studies indicated very small effect sizes. Evidence from compartment models, molecular imaging, and intervention studies remains sparse. Validation studies in experimental, histological, ex vivo, and cellular systems demonstrate that diffusion signals can reflect immune-related microstructural change but are not specific to inflammation. Future work should prioritize multimodal validation, mechanistically informed acquisition and modeling, and explicit testing of competing explanations. Once validated, dMRI could provide a scalable means of mapping immune-related microstructural change across the brain in mental illness.
- Open Access
- 15 September 2026
- Published by Springer Nature in Psychopharmacology
- p. 1-18
Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology
Psychedelics (hallucinogenic 5-HT 2A agonists such as psilocybin) are being investigated for their potential to treat a range of conditions, including anxiety-related psychopathology. Despite promising results, the mechanisms by which psychedelic therapy may alleviate anxiety are not well understood. Here, we review neural and cognitive mechanisms underlying anxiety-related psychopathology and how psychedelics may impact these mechanisms. This review culminates in a tentative neurocognitive account of how psychedelics may promote long-term anxiolysis. We propose a model of anxiety related psychopathology wherein anxiety-related contextual information from the hippocampus may influence amygdala and salience network activity, biasing information processing toward anxiety-related content that thereby is encoded by the hippocampus and perpetuates this cycle. We posit that psychedelic may acutely free cortical networks from hippocampal-dependent contextual constraints in part through 5-HT 2A expression on excitatory and inhibitory neurons in the cortex and hippocampus, respectively, while the intrinsic plasticity of the hippocampus and/or psychedelic-mediated plasticity allows for a “resetting of the hippocampal buffer.” Following acute effects, increased cortical plasticity may enable the hippocampus to adaptively integrate novel information into a contextual frame less biased or constrained by prior aversive conditioning, promoting an overall reduction in anxious thoughts and appraisals. We end by discussing potential challenges of psychedelic therapy for anxiety, and suggest directions for future research to determine the optimal treatment paths informed by cognitive neuroscience.
- 15 September 2026
- Published by Springer Nature in Psychopharmacology
- p. 1-18
Open AccessResetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology
Psychedelics (hallucinogenic 5-HT 2A agonists such as psilocybin) are being investigated for their potential to treat a range of conditions, including anxiety-related psychopathology. Despite promising results, the mechanisms by which psychedelic therapy may alleviate anxiety are not well understood. Here, we review neural and cognitive mechanisms underlying anxiety-related psychopathology and how psychedelics may impact these mechanisms. This review culminates in a tentative neurocognitive account of how psychedelics may promote long-term anxiolysis. We propose a model of anxiety related psychopathology wherein anxiety-related contextual information from the hippocampus may influence amygdala and salience network activity, biasing information processing toward anxiety-related content that thereby is encoded by the hippocampus and perpetuates this cycle. We posit that psychedelic may acutely free cortical networks from hippocampal-dependent contextual constraints in part through 5-HT 2A expression on excitatory and inhibitory neurons in the cortex and hippocampus, respectively, while the intrinsic plasticity of the hippocampus and/or psychedelic-mediated plasticity allows for a “resetting of the hippocampal buffer.” Following acute effects, increased cortical plasticity may enable the hippocampus to adaptively integrate novel information into a contextual frame less biased or constrained by prior aversive conditioning, promoting an overall reduction in anxious thoughts and appraisals. We end by discussing potential challenges of psychedelic therapy for anxiety, and suggest directions for future research to determine the optimal treatment paths informed by cognitive neuroscience.
- Open Access
An updated roadmap for brain-mental health associations in the UK Biobank
The UK Biobank offers an unprecedented opportunity to examine associations between brain imaging and mental health at scale, but their magnitude and replicability remain unclear. We correlated 17,580 imaging-derived phenotypes across seven MRI modalities with 309 mental health phenotypes in 8,415 participants, split into discovery and validation subsets. Associations were generally small (median |r| = 0.018; top 1% of 0.108), and they replicated poorly: only 9.0% of significant discovery associations were significant in validation. Eating disorders showed the largest effects of any mental disorders but replicated in only 6.0% of cases, whereas substance use showed the highest replication (14.5%). Susceptibility-weighted imaging produced the most replicable imaging associations. Longitudinal changes in brain and mental health measures were weakly related. We provide an interactive dashboard that returns the effect-size and replicability benchmarks for any combination of mental health category and imaging modality, supporting variable selection and study design in UK Biobank research.
Open AccessAn updated roadmap for brain-mental health associations in the UK Biobank
The UK Biobank offers an unprecedented opportunity to examine associations between brain imaging and mental health at scale, but their magnitude and replicability remain unclear. We correlated 17,580 imaging-derived phenotypes across seven MRI modalities with 309 mental health phenotypes in 8,415 participants, split into discovery and validation subsets. Associations were generally small (median |r| = 0.018; top 1% of 0.108), and they replicated poorly: only 9.0% of significant discovery associations were significant in validation. Eating disorders showed the largest effects of any mental disorders but replicated in only 6.0% of cases, whereas substance use showed the highest replication (14.5%). Susceptibility-weighted imaging produced the most replicable imaging associations. Longitudinal changes in brain and mental health measures were weakly related. We provide an interactive dashboard that returns the effect-size and replicability benchmarks for any combination of mental health category and imaging modality, supporting variable selection and study design in UK Biobank research.
- Open Access
- 9 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (7) , e71574
Psychedelics in Mental Health: Opportunities and Challenges
Psychedelic and substance‐assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment‐resistant depression, post‐traumatic stress disorder, and substance use disorders. However, as the field moves from early efficacy trials toward clinical implementation, major questions remain regarding therapeutic mechanisms, psychological support models, safety, ethics, accessibility, and the role of subjective experience. This editorial introduces the Brain and Behavior special issue “Psychedelics in Mental Health: Opportunities and Challenges,” which brings together empirical studies, reviews, clinical perspectives, a case report, and commentaries addressing these emerging priorities. Across the special issue, a central theme is that psychedelic therapy cannot be understood as a pharmacological intervention alone. Contributions highlight the importance of therapeutic relationships, preparation, integration, music, touch, external therapist involvement, peer support, cultural context, and patient expectations in shaping outcomes. Several manuscripts examine the phenomenology of psychedelic and ketamine experiences, emphasizing that subjective meaning‐making, expectancy, and altered states are not incidental features but potentially central aspects of therapeutic change and clinical risk. Other articles consider implementation challenges, including models of care for veterans, the perspectives of peer support workers, global mental health equity, and culturally responsive access. Mechanistic and translational work further broadens the field by examining neuroplasticity, rapid‐acting interventions for suicidality, and developmental perspectives on psychedelic use. Collectively, the articles in this special issue illustrate a field at an important inflection point. Psychedelic research requires greater conceptual precision, careful attention to safety and consent, and implementation frameworks that prioritize equity and cultural appropriateness. The promise of psychedelics in mental health lies not only in their potential for rapid symptom reduction, but also in their capacity to challenge and expand prevailing models of therapeutic change, integrating biological, psychological, relational, cultural, and systems‐level perspectives on healing.
- 9 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (7) , e71574
Open AccessPsychedelics in Mental Health: Opportunities and Challenges
Psychedelic and substance‐assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment‐resistant depression, post‐traumatic stress disorder, and substance use disorders. However, as the field moves from early efficacy trials toward clinical implementation, major questions remain regarding therapeutic mechanisms, psychological support models, safety, ethics, accessibility, and the role of subjective experience. This editorial introduces the Brain and Behavior special issue “Psychedelics in Mental Health: Opportunities and Challenges,” which brings together empirical studies, reviews, clinical perspectives, a case report, and commentaries addressing these emerging priorities. Across the special issue, a central theme is that psychedelic therapy cannot be understood as a pharmacological intervention alone. Contributions highlight the importance of therapeutic relationships, preparation, integration, music, touch, external therapist involvement, peer support, cultural context, and patient expectations in shaping outcomes. Several manuscripts examine the phenomenology of psychedelic and ketamine experiences, emphasizing that subjective meaning‐making, expectancy, and altered states are not incidental features but potentially central aspects of therapeutic change and clinical risk. Other articles consider implementation challenges, including models of care for veterans, the perspectives of peer support workers, global mental health equity, and culturally responsive access. Mechanistic and translational work further broadens the field by examining neuroplasticity, rapid‐acting interventions for suicidality, and developmental perspectives on psychedelic use. Collectively, the articles in this special issue illustrate a field at an important inflection point. Psychedelic research requires greater conceptual precision, careful attention to safety and consent, and implementation frameworks that prioritize equity and cultural appropriateness. The promise of psychedelics in mental health lies not only in their potential for rapid symptom reduction, but also in their capacity to challenge and expand prevailing models of therapeutic change, integrating biological, psychological, relational, cultural, and systems‐level perspectives on healing.
- Open Access
- 29 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Repeated Exposure: Baseline Symptom Severity Moderates the Efficacy of Virtual Reality (VR) Compassion Training: Secondary Analysis of a Sequentially-Allocated Controlled Trial (Preprint)
BACKGROUND Virtual Reality (VR) is increasingly utilised for delivering compassion-focused interventions. However, existing research often aggregates data from minimal and elevated symptomatic samples, potentially masking distinct symptom trajectories and obscuring how individuals with varying levels of baseline distress respond to highly immersive therapeutic environments. OBJECTIVE This study investigated whether baseline symptom severity moderates the efficacy of a VR self-compassion training paradigm, aiming to determine if distinct recovery trajectories emerge between minimal and elevated distress cohorts. METHODS We conducted a secondary analysis of a sequentially-allocated controlled trial. Participants (N = 65) were classified into “Minimal” (n = 31) or “Elevated” (n = 34) distress groups based on baseline Depression and Anxiety scores on the DASS-21. All participants completed two sessions of an immersive VR self-compassion intervention. Symptom trajectories (Depression and Anxiety) were analysed across four timepoints using mixed ANOVAs to evaluate immediate and inter-session symptom responses. RESULTS Anxiety decreased significantly across both the minimal and elevated groups, indicating a robust, transdiagnostic soothing effect (main effect of Time: p = .009). For depression, the elevated group displayed a theoretically predicted non-linear trajectory of initial reduction followed by inter-session recurrence, though the Time x Symptom Status interaction was marginally significant (p = .058). The clinical impact of the intervention was substantial; following the second session, 44.1% (15/34) of the elevated distress cohort successfully reached minimal symptom levels. CONCLUSIONS VR functions as a robust safety signal for rapidly down-regulating threat arousal and anxiety, irrespective of baseline severity. Conversely, the volatile response observed in depression aligns with theoretical cognitive resistance to compassion. These findings highlight the necessity of multi-session VR protocols for individuals with elevated pathology to effectively integrate the physiological activation of the soothing system and overcome cognitive blocks. CLINICALTRIAL N/A
- 29 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessRepeated Exposure: Baseline Symptom Severity Moderates the Efficacy of Virtual Reality (VR) Compassion Training: Secondary Analysis of a Sequentially-Allocated Controlled Trial (Preprint)
BACKGROUND Virtual Reality (VR) is increasingly utilised for delivering compassion-focused interventions. However, existing research often aggregates data from minimal and elevated symptomatic samples, potentially masking distinct symptom trajectories and obscuring how individuals with varying levels of baseline distress respond to highly immersive therapeutic environments. OBJECTIVE This study investigated whether baseline symptom severity moderates the efficacy of a VR self-compassion training paradigm, aiming to determine if distinct recovery trajectories emerge between minimal and elevated distress cohorts. METHODS We conducted a secondary analysis of a sequentially-allocated controlled trial. Participants (N = 65) were classified into “Minimal” (n = 31) or “Elevated” (n = 34) distress groups based on baseline Depression and Anxiety scores on the DASS-21. All participants completed two sessions of an immersive VR self-compassion intervention. Symptom trajectories (Depression and Anxiety) were analysed across four timepoints using mixed ANOVAs to evaluate immediate and inter-session symptom responses. RESULTS Anxiety decreased significantly across both the minimal and elevated groups, indicating a robust, transdiagnostic soothing effect (main effect of Time: p = .009). For depression, the elevated group displayed a theoretically predicted non-linear trajectory of initial reduction followed by inter-session recurrence, though the Time x Symptom Status interaction was marginally significant (p = .058). The clinical impact of the intervention was substantial; following the second session, 44.1% (15/34) of the elevated distress cohort successfully reached minimal symptom levels. CONCLUSIONS VR functions as a robust safety signal for rapidly down-regulating threat arousal and anxiety, irrespective of baseline severity. Conversely, the volatile response observed in depression aligns with theoretical cognitive resistance to compassion. These findings highlight the necessity of multi-session VR protocols for individuals with elevated pathology to effectively integrate the physiological activation of the soothing system and overcome cognitive blocks. CLINICALTRIAL N/A
- Open Access
- 28 May 2026
- Published by Center for Open Science in PsyArXiv
Dismantling the Mechanism of VR Self-Compassion Training: A Two-Session Controlled Trial with Active Controls
Objectives. While prior research suggests that self-compassion training delivered via virtual reality (VR) is effective, it is limited by the absence of appropriate control conditions. Using a two-session, randomised controlled trial (RCT) design, this study compared a conventional VR self-compassion training paradigm to two active control conditions: a non-VR, computer-based self-compassion training, and a VR intervention that replaced the self-to-self component with a generic third-party interaction (VR Generic). Method. Eighty-nine participants completed the training. Primary (self-compassion, self-criticism) and secondary (depression, anxiety, stress) outcomes were assessed pre- and post-intervention. Exploratory analyses examined virtual embodiment (agency, ownership, self-location) as a mechanism of change. Results. No significant group differences emerged for anxiety, stress, or self-compassion. However, distinct efficacy patterns emerged for specific symptoms. For depression, the externally focused VR Generic condition demonstrated a preliminary advantage for symptom reduction compared to the computer control. Conversely, for self-criticism, the self-focused VR Self-Compassion training was significantly more effective than both controls. Both VR conditions induced higher agency than the computer control, but only the self-focused VR condition increased body ownership. This heightened embodiment, however, did not universally translate into superior wellbeing benefits across all domains. Conclusions. The findings suggest that specific VR formats may be better suited for targeting distinct psychological symptoms. While externally focused VR shows promise for alleviating depressive symptoms, the embodied “self-to-self” simulation appears critical for dismantling self-criticism. Rather than acting as a universally superior intervention, VR embodiment may offer a targeted approach tailored to specific symptom presentations.
- 28 May 2026
- Published by Center for Open Science in PsyArXiv
Open AccessDismantling the Mechanism of VR Self-Compassion Training: A Two-Session Controlled Trial with Active Controls
Objectives. While prior research suggests that self-compassion training delivered via virtual reality (VR) is effective, it is limited by the absence of appropriate control conditions. Using a two-session, randomised controlled trial (RCT) design, this study compared a conventional VR self-compassion training paradigm to two active control conditions: a non-VR, computer-based self-compassion training, and a VR intervention that replaced the self-to-self component with a generic third-party interaction (VR Generic). Method. Eighty-nine participants completed the training. Primary (self-compassion, self-criticism) and secondary (depression, anxiety, stress) outcomes were assessed pre- and post-intervention. Exploratory analyses examined virtual embodiment (agency, ownership, self-location) as a mechanism of change. Results. No significant group differences emerged for anxiety, stress, or self-compassion. However, distinct efficacy patterns emerged for specific symptoms. For depression, the externally focused VR Generic condition demonstrated a preliminary advantage for symptom reduction compared to the computer control. Conversely, for self-criticism, the self-focused VR Self-Compassion training was significantly more effective than both controls. Both VR conditions induced higher agency than the computer control, but only the self-focused VR condition increased body ownership. This heightened embodiment, however, did not universally translate into superior wellbeing benefits across all domains. Conclusions. The findings suggest that specific VR formats may be better suited for targeting distinct psychological symptoms. While externally focused VR shows promise for alleviating depressive symptoms, the embodied “self-to-self” simulation appears critical for dismantling self-criticism. Rather than acting as a universally superior intervention, VR embodiment may offer a targeted approach tailored to specific symptom presentations.
- Open Access
- 22 May 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 411, 122017
Trajectory classes of post-stroke depression severity and their baseline predictors: A multi-cohort replication study
- 22 May 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 411, 122017
Open AccessTrajectory classes of post-stroke depression severity and their baseline predictors: A multi-cohort replication study